Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
Neuroscientist. 2011 Jun;17(3):244-55. doi: 10.1177/1073858410385006. Epub 2011 Jan 20.
Parkinson disease (PD) is second only to Alzheimer disease as the most common neurodegenerative disorder in humans. Despite intense investigations, no effective therapy is available to halt the progression of PD. Although statins are widely used cholesterol-lowering drugs throughout the world, recent studies suggest that these drugs modulate neurodegeneration-related signaling processes and may be beneficial for PD. Simvastatin is the most potent statin in crossing the blood-brain barrier, and this particular statin drug negatively correlates with the incidence of PD and shows efficacy in animal models of PD. However, PD mainly occurs in the aging population, who are more vulnerable to cholesterol or lipid-related disorders, raising questions whether this possible beneficial effect of statins in PD patients is cholesterol dependent or cholesterol independent. This article presents data on the therapeutic efficacy of simvastatin in a chronic MPTP model of PD, reviews recent literature, and discusses the pros and cons of statin therapy in PD.
帕金森病（PD）是仅次于阿尔茨海默病的人类第二常见神经退行性疾病。尽管进行了深入研究，但仍没有有效的治疗方法可以阻止 PD 的进展。尽管他汀类药物在全球范围内被广泛用作降胆固醇药物，但最近的研究表明，这些药物可以调节与神经退行性相关的信号转导过程，并且可能对 PD 有益。辛伐他汀是穿过血脑屏障最有效的他汀类药物，这种特定的他汀类药物与 PD 的发病率呈负相关，并在 PD 的动物模型中显示出疗效。然而，PD 主要发生在老年人群中，他们更容易受到胆固醇或脂质相关疾病的影响，这引发了一个问题，即他汀类药物在 PD 患者中的这种可能有益作用是否依赖于胆固醇或与胆固醇无关。本文介绍了辛伐他汀在慢性 MPTP 诱导的 PD 模型中的治疗效果的数据，综述了最近的文献，并讨论了他汀类药物治疗 PD 的利弊。
